Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon hybrid
- Development stage
- Preclinical
- Lead developer
- Heligenics
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Interferon hybrid is a recombinant interferon hybrid protein (a single-molecule, two-gene hybrid) being developed by Heligenics for the treatment of multiple sclerosis. Discovered and optimized using Heligenics' proprietary GigaAssay™ high-throughput functional screening platform, this hybrid protein is engineered from multiple interferon genes to optimize potency, safety, and efficacy. It is designed to activate interferon receptor signaling, mimicking or improving upon natural type I interferon activity to reduce the excessive inflammation and neurodegeneration associated with multiple sclerosis.
- Other names
- Interferon hybrid (1 molecule, two-gene hybrid)interferon hybrid proteintwo-gene interferon hybrid
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on interferon hybrid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon hybrid.